方正证券股份有限公司 2025 年第一次临时股东大会 会议资料 2025 年 12 月 12 日·北京 会议议程 现场会议时间：2025 年 12 月 12 日 14:30 现场会议地点：北京市朝阳区朝阳门南大街 10 号兆泰国际中心 A 座 19 层会议室 1 一、宣布会议开始 二、宣布出席现场会议的股东人数、代表股份数 三、推举计票人、监票人 四、审议议案 五、股东提问，董事、监事、高管人员回答股东提问 六、投票表决 七、休会（等待网络表决结果，工作人员统计表决结果） 八、宣布表决结果 九、律师宣布法律意见书 十、宣布会议结束 方正证券股份有限公司 2025年第一次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大 会的顺利召开，根据中国证监会《上市公司股东大会规则》、公司《章程》和《股 东大会议事规则》等规定，特制定股东大会会议须知如下： 一、本公司根据《公司法》《证券法》《上市公司股东大会规则》和公司《章 程》的规定，认真做好召开股东大会的各项工作。 二、股东大会期间，全体参会人员应以维护股东的合法权益、确保大会的正 常秩序和议事效率为原则，依法行使权利，认真履行 ...

证券代码：601901 证券简称：方正证券 公告编号：2025-048 方正证券股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 （一）股东大会类型和届次 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 12 日 至2025 年 12 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通 2025年第一次临时股东大会 （二）股东大会召集人：董事会 （三）投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 12 日 14 点 30 分 召开地点：北京市朝阳区朝阳门南大街 10 号兆泰国际中心 A 座 19 层会议室 1 ...

证券代码：601901 证券简称：方正证券 公告编号：2025-045 方正证券股份有限公司 第五届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司第五届监事会第十二次会议于 2025 年 11 月 26 日以现场加视频的方式在 公司会议室召开。本次会议的通知和会议资料于 2025 年 11 月 20 日以电子邮件方 式发出，本次会议由监事会主席蔡平女士召集和主持，应出席监事 3 名，实际出 席监事 3 名（蔡平女士和陈曦女士视频参会，徐国华先生现场参会），董事会秘书 列席了会议。本次会议的召集、召开程序符合《公司法》、公司《章程》的有关规 定。 经审议，本次会议形成如下决议： 审议通过了《关于不再设立监事会的议案》 监事会同意公司不再设立监事会和监事，并废止《监事会议事规则》。 此项议案需提交股东大会审议。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 方正证券股份有限公司监事会 2025 年 11 月 26 日 ...

证券代码：601901 证券简称：方正证券 公告编号：2025-046 方正证券股份有限公司 第五届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 公司第五届董事会第十九次会议于 2025 年 11 月 26 日以现场加视频的方式在公司 会议室召开。本次会议的通知和会议资料于 2025 年 11 月 20 日以电子邮件方式发出。 本次会议由董事长施华先生召集和主持，应出席董事 9 名，实际出席董事 9 名（施华 先生、张路先生、曹诗男女士、林钟高先生、柯荣富先生视频参会，姜志军先生、李 岩先生、宋洪军先生、张忠民女士现场参会），公司 3 名监事、董事候选人邹昊先生、 独立董事候选人薛军先生和部分高级管理人员列席了会议。本次会议的召集、召开程 序符合《公司法》、公司《章程》的有关规定。 经审议，本次会议形成如下决议： 一、审议通过了《关于修订公司〈章程〉及相关议事规则的议案》 董事会同意修订公司《章程》及《股东大会议事规则》《董事会议事规则》的部分 条款，其中《股东大会议事规则》更名为《股东会议事规则 ...

Market Overview - The participatory fund sector experienced a decline of 0.84% compared to the previous trading day, with Daheng Technology leading the drop [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Notable gainers included: - Zhongjia Group (Code: 000039) with a closing price of 9.35, up 10.00% and a trading volume of 1.9474 million shares, totaling 1.764 billion yuan [1] - Suzhou Gaoxin (Code: 600736) closed at 5.79, up 3.76% with a trading volume of 590,000 shares, totaling 345 million yuan [1] - Daheng Technology (Code: 600288) was the biggest loser, closing at 14.69, down 2.13% with a trading volume of 86,400 shares, totaling 129 million yuan [2] Capital Flow - The participatory fund sector saw a net outflow of 732 million yuan from institutional investors, while retail investors contributed a net inflow of 574 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their participation [2] Individual Stock Capital Flow - Zhongjia Group (Code: 000039) had a net inflow of 474 million yuan from institutional investors, representing 26.86% of its trading volume [3] - Fenghuo Communication (Code: 600498) experienced a net inflow of 76.36 million yuan from institutional investors, but a net outflow of 18.29 million yuan from speculative funds [3]

Group 1: Core Insights - The current wave of innovative drugs is driven by China's participation in new technologies, with advancements in ADC, bispecific antibodies, second-generation IO, and GLP-1 [1] - The global pharmaceutical transaction volume has steadily increased, with total transaction amounts rising from $56.9 billion to $187.4 billion over the past decade, while China's transaction amounts surged from $3.1 billion to $57.1 billion [1] - By 2024, China's transaction volume is expected to account for approximately 30% of global pharmaceutical transactions [1] Group 2: Sector Analysis - In oncology, the combination of IO and ADC therapies remains strong, with significant transactions in the PD-1 bispecific antibody space; the sales of Pembrolizumab are projected to reach $29.482 billion in 2024 [2] - The autoimmune disease sector is witnessing a shift as older drugs face patent expirations, with new opportunities emerging in Th2 and Th17 pathways; Dupilumab is expected to lead with $14.1 billion in sales in 2024 [2] - The cardiovascular and metabolic disease market continues to grow, with GLP-1 receptor agonists projected to exceed $50 billion in global sales in 2024 [3] Group 3: Future Technologies - New technologies such as next-generation ADCs, TCE therapies, universal/in vivo CART technologies, gene therapy, and small nucleic acid technologies are anticipated to lead future disease treatments [4]

Core Viewpoint - The recent regulatory actions against Founder Securities highlight significant compliance issues across various business lines, indicating a need for improved governance, internal controls, and compliance culture within the company [2][3][6]. Compliance Issues - Founder Securities' Guangzhou Jin Yu Er Street Securities Office received a warning letter from the Guangdong Securities Regulatory Bureau for five major violations, including sending answers to knowledge assessment questionnaires to investors and inadequate management of fund sales [2][3]. - The company has faced multiple regulatory penalties in recent years, reflecting ongoing concerns about its governance structure and internal controls [2][3]. Business Line Vulnerabilities - Violations have been particularly concentrated in branch operations, with issues such as unauthorized sales tasks assigned to unqualified personnel and breaches of client confidentiality [3][4]. - The investment banking sector has also been flagged for serious deficiencies, including inadequate due diligence and poor material review processes [3][4]. Research and Subsidiary Management - Compliance weaknesses in research operations were noted, with incidents of content leaks and unauthorized stock recommendations by analysts [4]. - Founder Securities has faced challenges in managing its subsidiaries, particularly in Hong Kong, where risk management was deemed insufficient [4]. Information Disclosure and Asset Quality - Regulatory scrutiny has increased regarding the company's financial asset investment returns and the quality of its disclosures, particularly in light of significant shareholder sell-offs and foreign capital withdrawal [5][6]. Recommendations for Improvement - To address these compliance issues, the company must enhance the authority and independence of its risk control systems and improve the integration of compliance metrics into performance evaluations [8]. - A cultural shift towards prioritizing compliance over mere performance metrics is essential for sustainable operations and regaining market trust [8].

Group 1: Talent Movement in Securities Firms - The rapid turnover of Chief Information Officers (CIOs) in the securities industry reflects a talent competition driven by industry transformation, with at least 13 firms changing their CIOs this year [1][2] - Notable movements include He Jiang, the former CIO of First Capital Securities, potentially returning to Southwest Securities, where he began his career [1][2] - The trend indicates a significant shift in the technology talent landscape within the securities sector, emphasizing the importance of technology investment [2] Group 2: Approval of Hard Technology Themed Funds - On November 21, 16 hard technology themed funds were approved, including several ETFs focused on artificial intelligence and chips, signaling a substantial influx of capital into the market [3][4] - This approval highlights ongoing policy support for technological innovation, with direct benefits expected for sectors like artificial intelligence and semiconductor industries [3][4] - The move is anticipated to enhance liquidity and market activity in the STAR Market, reinforcing investor confidence in the technology growth sector [4] Group 3: Fund Issuance Trends - The new fund issuance in 2025 has reached 1,340 funds with a total scale of approximately 1,044.6 billion, marking the seventh consecutive year of exceeding the trillion yuan threshold [4] - Active equity products, particularly stock and mixed funds, have become the dominant force in new fund issuance, contributing over half of the total scale [4] - This trend reflects a long-term confidence in equity assets, benefiting asset management firms and potentially increasing capital inflows into the A-share market [4] Group 4: Transaction by Founder Securities - Founder Securities announced the completion of a share transfer of approximately 4.35 billion yuan from its holdings in Shengjing Bank, enhancing its liquidity and focusing on core business development [5][6] - This transaction may prompt market attention towards the divestment of non-core assets by securities firms, accelerating resource integration within the financial sector [6] - Overall, such capital operations are expected to boost investor confidence in the governance optimization of financial enterprises, providing a positive market signal [6]

Core Points - The company has agreed to sell 300 million shares of Shengjing Bank at a price of 1.45 yuan per share to Shenyang Shengjing Jin控 Investment Group [1] - The transfer of shares has been completed, and the company received a payment of 434.925 million yuan after deducting relevant fees [1] Summary by Sections - **Transaction Details** - The board of directors approved the sale of shares to Shengjing Jin控 at a price of 1.45 yuan per share [1] - The total payment received for the shares was 434.925 million yuan [1] - **Completion of Transfer** - The share transfer has been successfully registered [1] - The company no longer holds any shares in Shengjing Bank following the transaction [1]

Core Points - On November 21, 2025, the company announced the acceptance of an offer from Shenyang Shengjing Jin控 Investment Group Co., Ltd. to sell 300 million shares of Shengjing Bank at a price of 1.45 yuan per share [1] - The transfer of shares has been completed, and the company no longer holds any shares in Shengjing Bank [1] - The company received a payment of 434.925 million yuan for the share transfer after deducting relevant fees [1]